Press release | Official website vaccine against COVID-19 Sputnik V.

Main
Newsroom
Press Releases

Press Releases

A clinical study of the combination of AstraZeneca and Sputnik Light vaccines in Azerbaijan shows strong neutralizing antibodies growth in the majority of participants

Press release, 27.09.2021

The single-component Sputnik Light vaccine authorized in Egypt

Press release, 24.09.2021

The single-component Sputnik Light vaccine authorized in Iran

Press release, 15.09.2021

Sputnik V demonstrates 97.2% efficacy and high safety profile against COVID during the vaccination campaign in Belarus

Press release, 15.09.2021

Study on Sputnik Light (first component of Sputnik V) vaccine’s efficacy among the elderly in Argentina published in EClinicalMedicine journal

Press release, 13.09.2021

The single-component Sputnik Light vaccine authorized in Armenia

Press release, 06.09.2021

Sputnik V demonstrates 94.8% efficacy against COVID during the vaccination campaign in San Marino

Press release, 02.09.2021

A new study in Argentina on Sputnik V: “Our observations suggest that protection increases over 6 months following vaccination as a consequence of antibody maturation, resulting in improved potency of antibodies to viral escape mutations.”

Press release, 25.08.2021

Indonesia becomes the 70th country to approve the Sputnik V vaccine

Press release, 25.08.2021

The single-component Sputnik Light vaccine authorized in Philippines

Press release, 23.08.2021

3 4 5 6 7